Peng Pan, Ph.D.
About Peng Pan, Ph.D.
Peng Pan, Ph.D., serves as the Vice President of Nonclinical Development at Mythic Therapeutics, Inc., where he oversees the development of IHC-based biomarkers and companion diagnostics. With extensive experience in biotherapeutics development, he has held key positions at notable companies such as Sanofi Genzyme, GSK, Shire, and Abbott.
Work at Mythic Therapeutics
Currently, Peng Pan serves as Vice President of Nonclinical Development at Mythic Therapeutics, Inc., a position held since 2023. In this role, he oversees the development of IHC-based biomarkers and companion diagnostics (CDx) at external vendors, ensuring that key validation milestones are met. He leads early hypothesis-driven investigations into mechanisms of toxicity, focusing on proactive management of potential safety liabilities. His work involves collaboration with a team of external expert consultants to advance development programs effectively.
Previous Experience in Biopharmaceuticals
Peng Pan has extensive experience in the biopharmaceutical sector. He worked at Sanofi Genzyme from 2005 to 2015, where he held various roles including Senior Scientist and Staff Scientist II. Following this, he served as BBD Lead for Bioanalytical and Biomarker Development at Shire from 2015 to 2018. He then transitioned to GSK as Scientific Director for DMPK and Bioanalytical Sciences from 2018 to 2021. His roles have involved significant contributions to global biotherapeutics development.
Educational Background
Peng Pan holds a Doctor of Philosophy (Ph.D.) in Analytical Chemistry from Purdue University. He also earned a Master of Science (MS) in Organic Chemistry from Bowling Green State University. His academic journey began with a Bachelor of Science (BS) in Analytical Chemistry from Wuhan University. This strong educational foundation has equipped him with the necessary skills for his career in the biopharmaceutical industry.
Regulatory Expertise and Contributions
In his professional capacity, Peng Pan has hands-on experience in authoring regulatory submission documents. He has directly interacted with health authorities to facilitate successful filings for Investigational New Drug (IND), Clinical Trial Applications (CTA), In Vitro Diagnostic Regulation (IVDR), New Drug Applications (NDA), Biologics License Applications (BLA), and Marketing Authorization Applications (MAA). His expertise in regulatory strategy is a vital component of his role in nonclinical development.
Leadership in Toxicity Investigations
Peng Pan leads initiatives focused on early hypothesis-driven investigations into mechanisms of toxicity. This proactive approach aims to manage potential safety liabilities effectively. He provides guidance on key conclusions and the potential impact of results on program and clinical/regulatory strategy, ensuring transparency and timeliness in communication with stakeholders.